Fig. 4

Lenalidomide treatment of MM cells affected degradation of AGO2. a & b The effects of lenalidomide treatment of My5.LV cells (a) or My5.CRBN cells (b) for 1 day. MM cells were treated with either DMSO (−) or 10 μM lenalidomide (+) for 18 hours and then 10 μM proteasome inhibitor MG132 (+) were added to the media for additional 6 hours. c & d The effects of lenalidomide treatment of My5.LV cells (c) or My5.CRBN cells (d) for 6 days. MM cells were treated with either DMSO (−) or 10 μM lenalidomide (+) for 138 hours and then 10 μM proteasome inhibitor MG132 (+) were added to the media for additional 6 hours. 100 μg of total proteins from whole cell lysates were loaded in each lane and analyzed by western blot. The intensity of β-actin band or the 67 kDa AGO2 degradation product in samples neither treated with lenalidomide nor MG132 was considered as 1 and the relative amount of β-actin or the 67 kDa AGO2 degradation product in other samples was calculated accordingly